

Association of the 12-gene Breast DCIS Score® assay with local recurrence in patients with ductal carcinoma in situ treated on accelerated partial breast radiotherapy protocols

Charles Leonard (✉ charles.leonard@usoncology.com)

Rocky Mountain Cancer Centers

Shannon Tole

Rocky Mountain Cancer Centers

Michelle Turner

Exact Sciences (United States)

John Bennett

Exact Sciences (United States)

Kathryn Howell

Rocky Mountain Cancer Centers

Dennis Carter

Rocky Mountain Cancer Centers

Research Article

Keywords: DCIS (ductal carcinoma in situ), Redwood City, CA, APBI (accelerated partial breast radiotherapy)

Posted Date: December 19th, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-116082/v1>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Background

The following analysis explores clinicopathologic factors and the 12-gene Breast DCIS Score test result in order to better define an appropriate DCIS (ductal carcinoma in situ) population eligible for APBI (accelerated partial breast radiotherapy).

Methods

This exploratory analysis aimed to retrospectively measure the association between the 12-gene Oncotype DX Breast DCIS Score® assay (Redwood City, CA) and relevant clinicopathologic factors with locoregional recurrence in a pooled cohort of women treated with local excision and APBI on prospective phase II (NCT01185145) and phase III (NCT01185132) clinical trials. Univariable Cox proportional hazards regression was used to determine whether there was an association between local recurrence and DCIS Score result risk group (≥ 39 vs < 39) and clinicopathologic factors.

Results

This analysis included 104 evaluable patients (n = 18 from NCT01185145 and n = 86 from NCT01185132). The median age was 60 years (range: 40–79). Seventy-nine percent of patients were postmenopausal. The median span of DCIS was 10 mm (range 2–45 mm). Two-thirds of the cohort presented with necrosis (71%). The distribution of DCIS Score® results ranged from 0 to 82, with 69% of patients having a DCIS Score result < 39 . The median follow-up time was 8.2 years in NCT01185145 versus 3.0 years in NCT01185132. There were 6 local ipsilateral breast recurrences. DCIS Score result was significantly associated with local recurrence in univariable modeling, hazard ratio = 10.3 (95% CI 1.7, 198.4); p = 0.010. None of the clinicopathologic characteristics resulted in any significant association with locoregional recurrence.

Conclusion

The Breast DCIS Score assay demonstrated risk stratification in this cohort of patients treated with local excision and APBI pooled from two clinical trials. These results are consistent with those recently published utilizing whole breast radiotherapy. Due to the small number of local recurrence events and limited follow-up time, further investigations are needed to confirm findings.

Introduction

Ductal carcinoma in situ (DCIS) is a proliferation of malignant epithelial cells of the ducts and terminal lobular units of the breast that do not invade the basement membrane. The incidence of DCIS has

increased markedly since the early 1980s probably due to the adoption of screening mammography.¹ Whole breast radiotherapy has largely been shown to benefit patients and has historically been standard of practice to treat breast DCIS after lumpectomy.²⁻⁸ Several trials have demonstrated that breast radiotherapy might be omitted as an adjuvant treatment in some DCIS patients with acceptably low recurrence risks.^{9,10}

The use of whole breast radiotherapy has been based on multiple trials showing a reduction in local recurrence but no improvement in survival. However, whole breast radiotherapy probably over-treats most patients. Newer strategies such as accelerated partial breast irradiation (APBI) have been utilized increasingly in patients considered to have a lower risk of local recurrence, especially those with breast DCIS. The updated American Society of Radiation Oncology (ASTRO) APBI guidelines have included "low risk" DCIS (defined by RTOG 9804 criteria) as suitable candidates for APBI.^{11,12}

Estimation of the risk of local recurrence after lumpectomy alone has been based on traditional clinicopathologic factors, such as patient age at diagnosis, DCIS grade, and tumor size. These factors were derived from clinical trials, population studies and other tools of risk calculation.^{13,14} The 12-gene Oncotype DX Breast DCIS Score® assay has been clinically validated to provide individual 10-year local recurrence risk estimates after breast conserving surgery (BCS) alone.^{15,16} The assay measures the RNA expression of 12 genes using RT-PCR in formalin-fixed paraffin-embedded tumor tissue. These studies also reported the significant correlation between the DCIS Score result and the risk of ipsilateral breast recurrence in DCIS patients after lumpectomy alone and the DCIS Score result maintained this significance even when other clinicopathologic factors are considered.^{15,16} Data from the two validation studies (E5194 and Ontario DCIS Cohort) were combined in a patient-specific meta-analysis that adjusted for pre-specified clinicopathologic factors (age, tumor size, and year of diagnosis) to provide refined estimates of the 10-year risk of local recurrence after BCS alone.¹⁷

The objective of the current analysis was to assess the correlation between the DCIS Score result and other clinicopathologic factors in the outcomes of women who underwent APBI on two prospective protocols. The hypothesis was that the DCIS Score result might be more informative than clinicopathologic factors alone in identifying patients with high risk disease who may not be "low-risk" candidates for APBI as described in ASTRO eligibility criteria.

Methods And Materials

An exploratory analysis was retrospectively performed to measure the association between clinicopathologic factors and the DCIS Score result and the risk of any local in situ or invasive recurrence. All patients were enrolled with signed informed consent on one of two treatment protocols: a prospective phase II (NCT01185145; WIRB 20040075; principal investigator, Dennis Carter) and phase III (NCT01185132; WIRB #20091193; principal investigator, Charles Leonard) clinical trials conducted by Rocky Mountain Cancer Centers (RMCC/US Oncology) and treated with local excision followed by APBI. All experimental protocol methods were approved by, well documented and according to Western

Institutional Review Board-Copernicus Group, (WIRB-CG, 1019 39th Ave., SE Suite 120, Puyallup, WA, 98374) protocol specifications, appropriate guidelines and regulations.

Estrogen receptor (ER) status, progesterone receptor (PR) status, and nuclear grade were determined centrally. Multifocal tumors were described only by local pathology and not determined or defined centrally. The presence of comedo necrosis was restricted to lesions with centrally necrotic ducts distended by cells exhibiting a pattern of growth consistent with ductal carcinoma in situ. The Breast DCIS Score assay was performed by quantitative RT-PCR on formalin-fixed paraffin-embedded DCIS tumor specimens in a central laboratory (Genomic Health, Inc., Redwood City, California).¹⁵ Descriptive statistics and assay results were derived both overall and by clinical trial cohort. Kaplan-Meier estimates of the risk of local recurrence were generated and a log rank test was performed to compare survival distributions after stratifying by DCIS Score risk groups. Because of the small number of events, the intermediate and high risk groups were combined into a single category (DCIS Score result ≥ 39) and compared with the low risk group (DCIS Score result < 39). Univariable Cox proportional hazards models were used to determine whether there was an association between local recurrence and categorized DCIS Score risk group or other clinicopathologic factors on the pooled cohort of clinical trial patients. The number of local recurrence events was expected to be low; therefore, the pre-specified analysis plan called for univariable analyses only. In order to reduce bias in the Cox model parameter estimates, Firth's correction was used.¹⁸ Due to the small sample size, profile-likelihood confidence intervals are reported.¹⁹ The data analysis was performed using SAS software, Version 9.4 of the SAS System for Windows. Graphics were created in SAS and R version 3.5.1 using the ggplot2 package.^{20,21}

Results

The DCIS tissue from 112 patients was available for the 12-gene assay (Fig. 1). Twenty-one patients had been enrolled into the phase II trial (NCT01185145) and 91 had been enrolled into the phase III trial (NCT01185132). Eight patients were excluded, 2 due to insufficient tumor and 6 due to insufficient RNA. The final analysis included 104 evaluable patients enrolled in both studies (18 from the phase II study and 86 from the phase III study).

Baseline characteristics of the combined cohort are presented in Table 1. The median age was 60 years (range: 40–79). Seventy-nine percent of patients were postmenopausal. The median span of DCIS was 10 mm (range 2–45 mm). The median phase II study follow-up time of 8.2 years was longer than the 3.0 years in the phase III study. Over two-thirds of the cohort presented with necrosis (71%). The distribution of DCIS Score results ranged from 0 to 82. Sixty-nine percent of patients had a DCIS Score result < 39 . There were differences between the two studies, however. The phase II study, which comprised approximately 17% of the patients in the entire cohort analyzed, notably included a younger cohort of patients and a slightly lower percentage of ER + patients than the phase III study. The phase III trial included a higher proportion of patients with a DCIS Score result < 39 than the phase II trial.

Table 1
Patient characteristics, overall and by clinical trial.

	Overall (N = 104)	NCT01185132 (Phase III study) (n = 86)	NCT01185145 (Phase II study) (n = 18)
Age at diagnosis, years			
Median (range)	60 (40–79)	61 (40–79)	57 (44–66)
40–49	16 (15%)	10 (12%)	6 (33%)
50–59	34 (33%)	28 (33%)	6 (33%)
60–69	40 (38%)	34 (40%)	6 (33%)
70–79	13 (13%)	13 (15%)	0
Missing	1 (1%)	1 (1%)	0
Menopausal status			
Pre	22 (21%)	16 (19%)	6 (33%)
Post	82 (79%)	70 (81%)	12 (67%)
ER status			
Negative	10 (10%)	7 (8%)	3 (17%)
Positive	94 (90%)	79 (92%)	15 (83%)
PR status			
Negative	20 (19%)	12 (14%)	8 (44%)
Positive	84 (81%)	74 (86%)	10 (56%)
Nuclear grade			
1	7 (7%)	7 (8%)	0
2	56 (54%)	46 (53%)	10 (56%)
3	38 (37%)	31 (36%)	7 (39%)

ER: estrogen receptor; PR: progesterone receptor.

^a A Phase III Randomized Study Comparing Intensity Modulated Planning Versus 3-Dimensional Planning for Accelerated Partial Breast Radiotherapy (2009-APBI); NCT01185132; WIRB #20091193.

^b A Phase II Accelerated Partial Breast Radiotherapy With Either Mammosite or Intensity Modulated Radiotherapy (APBI); NCT01185145; WIRB 20040075.

	Overall (N = 104)	NCT01185132 (Phase III study) (n = 86)	NCT01185145 (Phase II study) (n = 18)
Missing	3 (3%)	2 (2%)	1 (6%)
Comedo necrosis			
Not present	30 (29%)	26 (30%)	4 (22%)
Present	74 (71%)	60 (70%)	14 (78%)
Size (span of DCIS), mm			
Median (range)	10 (2–45)	10 (3–45)	9 (2–40)
≤ 10	54 (52%)	44 (51%)	10 (56%)
10 to 25	40 (38%)	35 (41%)	5 (28%)
> 25	10 (10%)	7 (8%)	3 (17%)
Multifocality			
No	95 (91%)	83 (97%)	12 (67%)
Yes	9 (9%)	3 (3%)	6 (33%)
Margin width, mm			
Median (range)	7 (0–85)	5 (0–85)	8 (2–11)
≥ 10	36 (35%)	29 (34%)	7 (39%)
5 to < 10	29 (28%)	23 (27%)	6 (33%)
3 to < 5	26 (25%)	23 (27%)	3 (17%)
< 3	13 (13%)	11 (13%)	2 (11%)
DCIS Score result			
Median (range)	27 (0–82)	25 (0–82)	38 (8–79)
< 39	72 (69%)	63 (73%)	9 (50%)

ER: estrogen receptor; PR: progesterone receptor.

^a A Phase III Randomized Study Comparing Intensity Modulated Planning Versus 3-Dimensional Planning for Accelerated Partial Breast Radiotherapy (2009-APBI); NCT01185132; WIRB #20091193.

^b A Phase II Accelerated Partial Breast Radiotherapy With Either Mammosite or Intensity Modulated Radiotherapy (APBI); NCT01185145; WIRB 20040075.

	Overall (N = 104)	NCT01185132 (Phase III study) (n = 86)	NCT01185145 (Phase II study) (n = 18)
≥ 39	32 (31%)	23 (27%)	9 (50%)
Follow-up time since DCIS diagnosis, years			
Median (range)	4.2 (0.6– 10.2)	3.0 (0.6–7.6)	8.2 (1.5–10.2)
ER: estrogen receptor; PR: progesterone receptor.			
^a A Phase III Randomized Study Comparing Intensity Modulated Planning Versus 3-Dimensional Planning for Accelerated Partial Breast Radiotherapy (2009-APBI); NCT01185132; WIRB #20091193.			
^b A Phase II Accelerated Partial Breast Radiotherapy With Either Mammosite or Intensity Modulated Radiotherapy (APBI); NCT01185145; WIRB 20040075.			

There were 6 local recurrences: 1 in the subgroup of patients with DCIS Score result < 39 (from the phase II trial) and 5 in the subgroup of patients with DCIS Score result ≥ 39 (3 from the phase III trial and 2 from the phase II trial). The Kaplan-Meier curves are displayed in Fig. 2. There was a statistically significant difference in the risk of local recurrence stratified by DCIS Score result ($p = 0.008$). A forest plot illustrates the result of the univariable Cox proportional hazards models for risk of local recurrence (Fig. 3). The DCIS Score result was significantly associated with local recurrence in univariable modeling (hazard ratio [HR] = 10.3 (95% CI 1.7, 198.4); $p = 0.010$). None of the clinicopathologic factors examined, such as age at diagnosis, menopausal status, central nuclear grading, presence of comedo necrosis, size, multifocality or margin width resulted in any significant correlation with locoregional recurrence. All results were highly variable due to the small number of events.

Discussion

A cohort of 104 patients with DCIS treated with APBI from two clinical trials was analyzed retrospectively to determine the utility of the DCIS Score result in identifying patients who may not be appropriate for APBI. Although the DCIS Score result has been shown to correlate significantly with local recurrence probability after lumpectomy only, there has only been limited evidence to suggest that the same correlation is true for patients who have had post-lumpectomy whole breast radiotherapy. This may be especially pertinent since ASTRO guidelines have recognized the appropriate use of APBI in lower risk DCIS without definitively specifying how objectively and consistently to classify DCIS patients.

Previously published studies stratified DCIS Score results into low risk (DCIS Score result < 39), intermediate risk (DCIS Score result between 39 and 54), and high risk (DCIS Score result ≥ 55).¹⁵ These three risk groups have estimated 10-year risks of local recurrence of 11%, 27% and 26%. After stratifying

patients into the low risk and combined intermediate and high risk groups, we found that 5 of the 6 local recurrences were in the intermediate and high risk groups.

Rakovitch et al. reported seminal information concerning post-lumpectomy whole breast radiotherapy.²² In their cohort of 689 lumpectomy patients with adjuvant whole breast radiotherapy, there was significant stratification of patients into three groups by increasing local recurrence risk. Low, intermediate and high risk DCIS Score result risk groups (< 39, 39–54, > 54) resulted in 7.5%, 13.6% and 20.5% 10 year ipsilateral breast recurrence ($p < 0.001$).

A higher local recurrence risk has been presented in several other reports. Nineteen percent and 20% of patients with poorly differentiated or solid/comedo type ductal carcinoma in situ in the EORTC study respectively failed locally after breast conservation surgery and whole breast radiotherapy.⁵ The Early Breast Cancer Trialists' Collaborative Group overview reported that roughly 17%-18% of patients with either high histologic or nuclear grade experienced local recurrence after conservative surgery and whole breast radiotherapy. Nineteen percent of patients with comedo/solid architecture present failed after similar treatment.²³

In contrast to the findings of the DCIS Score result, there was no apparent association between recurrence and any of the clinicopathologic factors (age, size, margin width, comedo necrosis or grade). While the number of recurrence events is small, there is a strong association between the DCIS Score result and recurrence risk that is not apparent when assessing risk with the traditional clinicopathologic factors. Thus, the DCIS Score result may be useful for identifying patients with higher risk of recurrence who may not be appropriate "low risk" candidates for APBI as defined by ASTRO guidelines.

Since the analysis cohort in this exploratory study was mostly from the phase III study, the small number of local recurrence events and limited follow-up time in the phase III trial, caution should be taken when interpreting the results. Further investigations are needed to confirm these findings and improve overall outcomes for women with DCIS.

Declarations

Competing Interests: No

References

1. Virnig BA, Shamliyan T, Tuttle TM, Kane RL, Wilt TJ. **Diagnosis and management of ductal carcinoma in situ (DCIS)**. *Evid Rep Technol Assess (Full Rep)*. 2009(185):1-549.
2. Fisher B, Dignam J, Wolmark N, et al. **Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17**. *J Clin Oncol*. 1998;16(2):441–452.

3. Emdin SO, Granstrand B, Ringberg A, et al. **SweDCIS: Radiotherapy after sector resection for ductal carcinoma in situ of the breast. Results of a randomised trial in a population offered mammography screening.** *Acta Oncol.* 2006;**45**(5):536–543.
4. Julien JP, Bijker N, Fentiman IS, et al. **Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853.** EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. *Lancet.* 2000;**355**(9203):528–533.
5. **Eortc Breast Cancer Cooperative Group, Eortc Radiotherapy Group, Bijker N, et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853—a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group.** *J Clin Oncol.* 2006;**24**(21):3381–3387.
6. Cuzick J, Sestak I, Pinder SE, et al. **Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial.** *Lancet Oncol.* 2011;**12**(1):21–29.
7. Patani N, Cutuli B, Mokbel K. **Current management of DCIS: a review.** *Breast Cancer Res Treat.* 2008;**111**(1):1–10.
8. Cuzick J. **Treatment of DCIS—results from clinical trials.** *Surg Oncol.* 2003;**12**(4):213–219.
9. Hughes LL, Wang M, Page DL, et al. **Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group.** *J Clin Oncol.* 2009;**27**(32):5319–5324.
10. McCormick B, Winter K, Hudis C, et al. **RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation.** *J Clin Oncol.* 2015;**33**(7):709–715.
11. Correa C, Harris EE, Leonardi MC, et al. **Accelerated Partial Breast Irradiation: Executive summary for the update of an ASTRO Evidence-Based Consensus Statement.** *Pract Radiat Oncol.* 2017;**7**(2):73–79.
12. Smith BD, Bellon JR, Blitzblau R, et al. **Radiation therapy for the whole breast: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline.** *Pract Radiat Oncol.* 2018;**8**(3):145–152.
13. Silverstein MJ. **The University of Southern California/Van Nuys prognostic index for ductal carcinoma in situ of the breast.** *Am J Surg.* 2003;**186**(4):337–343.
14. Rudloff U, Jacks LM, Goldberg JI, et al. **Nomogram for predicting the risk of local recurrence after breast-conserving surgery for ductal carcinoma in situ.** *J Clin Oncol.* 2010;**28**(23):3762–3769.
15. Solin LJ, Gray R, Baehner FL, et al. **A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast.** *J Natl Cancer Inst.* 2013;**105**(10):701–710.
16. Rakovitch E, Nofech-Mozes S, Hanna W, et al. **A population-based validation study of the DCIS Score predicting recurrence risk in individuals treated by breast-conserving surgery alone.** *Breast Cancer Res Treat.* 2015;**152**(2):389–398.

17. Rakovitch E, Gray R, Baehner FL, et al. Refined estimates of local recurrence risks and the impact of the DCIS score adjusting for clinico-pathological features: Meta-analysis of E5194 and Ontario DCIS cohort studies. 2017 ASCO Annual Meeting; 2017; Chicago, IL.
18. Heinze G, Schemper M. A solution to the problem of monotone likelihood in Cox regression. *Biometrics*. 2001;**57**(1):114–119.
19. Venzon DJ, Moolgavkar SH. A method for computing profile-likelihood-based confidence intervals. *Appl Statist*. 1988;**37**(1):87–94.
20. R Core Team. R: A language and environment for statistical computing. 2018. Accessed 27-Nov-2019.
21. Wickham H. *ggplot2: Elegant Graphics for Data Analysis*. New York: Springer-Verlag; 2016.
22. Rakovitch E, Nofech-Mozes S, Hanna W, et al. Multigene expression assay and benefit of radiotherapy after breast conservation in ductal carcinoma in situ. *J Natl Cancer Inst*. 2017;**109**(4):djw256.
23. Early Breast Cancer Trialists' Collaborative Group, Correa C, McGale P, et al. Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. *J Natl Cancer Inst Monogr*. 2010;**2010**(41):162–177.

Figures




Figure 1

Study flow diagram (N=104). a A Phase III Randomized Study Comparing Intensity Modulated Planning Versus 3-Dimensional Planning for Accelerated Partial Breast Radiotherapy (2009-APBI); NCT01185132;




Figure 2

Kaplan-Meier plot of ipsilateral recurrence-free survival by DCIS Score result. The table at the bottom of the figure shows the number at risk in even-numbered years since DCIS diagnosis.

Variable	HR (95% CI)	p-value
DCIS Score result		0.010
≥ 39 vs < 39	10.3 (1.7, 198.4)	
Age at diagnosis (years)		0.180
50 to 59 vs 40 to 49	0.8 (0.1, 5.8)	
60 to 79 vs 40 to 49	0.2 (<0.1, 1.6)	
Menopausal status		0.442
Post vs pre	0.5 (<0.1, 3.6)	
Nuclear grade (central)		0.885
2 vs 1	0.8 (<0.1, 112.9)	
3 vs 1	1.2 (0.1, 164.2)	
Comedo necrosis		0.206
Present vs not present	4.5 (0.5, 594.6)	
Size (span of DCIS), mm		0.566
> 10 to 25 vs ≤ 10	0.4 (<0.1, 2.3)	
> 25 vs ≤ 10	1.2 (0.1, 6.7)	
Multifocality		0.972
Yes vs no	1.0 (<0.1, 6.2)	
Margin width, mm		0.657
5 to < 10 vs ≥ 10	2.3 (0.3, 24.8)	
3 to < 5 vs ≥ 10	3.3 (0.4, 37.5)	
< 3 vs ≥ 10	2.7 (0.2, 33.8)	




Figure 3

Forest plot of univariable Cox proportional hazards models for risk of ipsilateral recurrence by the DCIS Score result and relevant demographic, clinical, and pathologic features.